ALNYLAM PHARMACEUTICALS INC (ALNY)       231.59  +2.57 (+1.12%)

231.59  +2.57 (+1.12%)

US02043Q1076 - Common Stock - After market: 231.59 0 (0%)

EPS Estimates (USD)

Recent Earnings VS Estimates
Period Reported Estimate Difference Surprise Q3 2022 -2.69 -1.80 -0.89-49.37% Q2 2022 -2.29 -1.67 -0.62-37.39% Q1 2022 -2.00 -1.88 -0.12-6.57% Q4 2021 -2.16 -1.57 -0.59-37.46% Q3 2021 -1.64 -1.60 -0.04-2.56% Q2 2021 -1.61 -1.65 0.042.16% Q1 2021 -1.71 -1.76 0.053.03% Q4 2020 -2.09 -1.74 -0.35-19.89%
Future EPS Estimates
Period Estimate Prior Growth (Y2Y) FY 2022 -9.64 -7.12 -35.43%Q4 2022 -1.87 -2.16 13.23%FY 2023 -5.74 -9.64 40.46%Q1 2023 -1.88 -2.00 6.16%Q2 2023 -1.85 -2.29 19.42%Q3 2023 -1.66 -2.69 38.42%Q4 2023 -1.42 -1.87 24.08%FY 2024 -1.45 -5.74 74.77%FY 2025 4.84 -1.45 434.39%FY 2026 9.47 4.84 95.48%FY 2027 18.40 9.47 94.34%

Revenue Estimates (USD)

Recent Revenue VS Estimates
Period Reported Estimate Difference Surprise Q3 2022 264.306M 297.59M -33.284M-11.18% Q2 2022 224.818M 261M -36.182M-13.86% Q1 2022 213.259M 248.24M -34.981M-14.09% Q4 2021 258.535M 238.3M 20.235M8.49% Q3 2021 187.633M 223.07M -35.437M-15.89% Q2 2021 220.553M 196.66M 23.893M12.15% Q1 2021 177.6M 172.11M 5.49M3.19% Q4 2020 163.6M 149.74M 13.86M9.26%
Future Revenue Estimates
Period Estimate Prior Growth (Y2Y) FY 2022 1.033B 844.287M 22.35%Q4 2022 318.59M 258.535M 23.23%FY 2023 1.521B 1.033B 47.24%Q1 2023 310.12M 213.259M 45.42%Q2 2023 335.96M 224.818M 49.44%Q3 2023 373.7M 264.306M 41.39%Q4 2023 426.47M 318.59M 33.86%FY 2024 2.249B 1.521B 47.86%FY 2025 2.861B 2.249B 27.21%FY 2026 3.895B 2.861B 36.14%FY 2027 5.373B 3.895B 37.95%